Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 476 | 85 | 381 |
| Samples | 199 | 47 | 149 |
| Peptides | 169 | 37 | 132 |
Function
MKRN1 · Makorin ring finger protein 1
This gene encodes a protein that belongs to a novel class of zinc finger proteins. The encoded protein functions as a transcriptional co-regulator, and as an E3 ubiquitin ligase that promotes the ubiquitination and proteasomal degradation of target proteins. The protein encoded by this gene is thought to regulate RNA polymerase II-catalyzed transcription. Substrates for this protein's E3 ubiquitin ligase activity include the capsid protein of the West Nile virus and the catalytic subunit of the telomerase ribonucleoprotein. This protein controls cell cycle arrest and apoptosis by regulating p21, a cell cycle regulator, and the tumor suppressor protein p53. Pseudogenes of this gene are present on chromosomes 1, 3, 9, 12 and 20, and on the X chromosome. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Apr 2014].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 136 amino-acid changes on canonical ENST00000255977 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MKRN1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MKRN1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Endometrial Carcinoma | 3/42 7% | 6/612 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 8/810 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 11/1390 1% |
| Melanoma | 6/210 3% | 14/1899 1% |
| Colorectal Carcinoma | 7/143 5% | 24/3239 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Other Solid Cancers | 3/94 3% | 8/1515 1% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 10/1592 1% |
| Gastric Carcinoma | 1/74 1% | 10/1809 1% |
| Neuroendocrine Tumour | 3/154 2% | 0/577 0% |
| Hepatocellular Carcinoma | 0/46 0% | 9/2210 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Bladder Carcinoma | 2/58 3% | 2/956 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Prostate Carcinoma | 0/13 0% | 8/2105 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Glioma | 1/52 2% | 5/2127 0% |
| Ovarian Carcinoma | 0/109 0% | 3/998 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 5/2550 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Neuroblastoma | 2/87 2% | 0/1331 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Breast Carcinoma | 0/144 0% | 4/3264 0% |
Mutation Distribution
Where MKRN1 is mutated · all tissues, split by cell line vs tissue
How many mutations in MKRN1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 476 mutations in MKRN1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|